IsoRay Releases First Disposable Delivery System for Prostate Cancer Treatment

IsoRay Inc., a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, has announced the summer release of its Build-Blu delivery system for real-time prostate brachytherapy.
 
The Build-Blu delivery system is a disposable, next-generation, seed stranding device that will allow prostate brachytherapists to affordably build custom-configured strands with Cesium-131 in the operating room, thereby allowing clinicians to individualize the procedure to the patient’s anatomy in real time. This new product will provide an alternative solution to the approximately 25 percent of treatment facilities for the prostate market that are using intra-operative techniques.
 
“We are excited to respond to market needs with this innovative solution for intra-operative construction of brachytherapy strands,” said William Cavanagh, chief science officer and chief operating officer of IsoRay. “This is the first disposable device for building strands in the operating room and uses a proprietary design to efficiently construct the individualized treatment plan. Further, we believe this is the first new delivery system designed specifically for prostate brachytherapy in years.”
 
“The Build-Blu delivery system will provide IsoRay with a differentiated solution, and position IsoRay to enter the intra-operative segment of the prostate brachytherapy market, estimated to account for approximately 25 percent, or $25 million of the $100 million prostate brachytherapy market,” added Thomas LaVoy, chairman and CEO of IsoRay. “The development of this device is an important part of the strategy that we first implemented 18 months ago by increasing our investment in the development of new products. The disposable loader is the first of its kind that not only addresses a void in IsoRay’s product line, but also in the market, by offering an affordable solution to practitioners. The product launch scheduled for this summer expands our addressable market and should help us solidify our position as a leader in prostate brachytherapy.”
 
IsoRay Inc., through its subsidiary, IsoRay Medical Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. The company is located in Richland, Wash.